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Vitamin D supplementation to patients 
with frequent respiratory tract infections: 
a post hoc analysis of a randomized 
and placebo-controlled trial
Peter Bergman1*, Anna‑Carin Norlin2, Susanne Hansen3 and Linda Björkhem‑Bergman1
Abstract 
Background: Vitamin D is considered to be important for a healthy immune system. The aim of this study was to test 
the hypothesis that vitamin D supplementation reduces number of respiratory tract infections (RTIs) and prolong the 
time to the first RTI in adult patients with frequent RTIs.
Methods: We performed a post hoc analysis of a randomized, placebo‑controlled and double‑blinded study, where 
adult patients with a high burden of RTIs were randomized to placebo or vitamin D (4000 IE/day for 1 year, n = 124 in 
the per protocol cohort presented here).
Results: Vitamin D supplementation increased the probability to stay free of RTI during the study year (RR 0.64, 95 % 
CI 0.43–0.94). Further, the total number of RTIs was also reduced in the vitamin D‑group (86 RTIs) versus placebo (120 
RTIs; p = 0.05). Finally, the time to the first RTI was significantly extended in the vitamin D‑group (HR 1.68, 95 % CI 
1.03–2.68, p = 0.0376).
Conclusion: Vitamin D supplementation was found to significantly increase the probability of staying infection free 
during the study period. This finding further supports the notion that vitamin D‑status should be monitored in adult 
patients with frequent RTIs and suggests that selected patients with vitamin D deficiency are supplemented. This 
could be a safe and cheap way to reduce RTIs and improve health in this vulnerable patient population.
The original trial was registered at http://www.clinicaltrials.gov (NCT01131858).
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Background
Vitamin D is considered to be important for a healthy 
immune system, by inducing expression of antimicro-
bial peptides in immune-cells and at epithelial surfaces 
[1]. In addition, vitamin D has broad anti-inflammatory 
effects on the adaptive immune system and can down-
regulate pro-inflammatory cytokines and increase 
immunoregulatory T-cells [2, 3]. Low levels of 25-hydrox-
yvitamin D (25-OHD) are associated with an increased 
risk of tuberculosis [4–6] and respiratory tract infections 
[7]. Previously, we have conducted a randomized, placebo 
controlled and double blind study where patients with 
primary immunodeficiency, with a high burden of infec-
tions, were randomized to placebo or vitamin D (4000 IE/
day for 1 year). In this study (n = 124), vitamin D supple-
mentation resulted in a significantly reduced infectious 
burden, compared to placebo. In addition, the total num-
bers of respiratory bacterial cultures were reduced by 
approximately 50 % and the antibiotic consumption was 
reduced by 60 % in the vitamin D-group [8].
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The primary endpoint in the original study was a com-
posite clinical score, based on a self-reported diary, as 
pre-specified in the original protocol. However, the pro-
tocol did not pre-define how an episode of acute respira-
tory infection (RTI) would be defined. Accordingly, this 
clinically relevant information was not reported in the 
original publication. Here we wanted to test the hypoth-
esis that vitamin D treated patients had fewer RTIs and 
also had a longer time to their first RTI, compared to pla-
cebo treated patients. To this end we carried out a post 
hoc analysis of our previously performed study [8].
Methods
Study cohort
The study cohort consisted of the per protocol popula-
tion (n  =  124) from our previously performed clinical 
trial [8]. The original trial was a prospective, randomized 
and double-blinded placebo-controlled study of vitamin 
D3 supplementation to patients with primary immunode-
ficiency and increased susceptibility to respiratory tract 
infections, described in details elsewhere [8]. Patients 
were recruited at the Immunodeficiency Unit, Karolin-
ska University Hospital, Huddinge, Sweden. Inclusion 
occurred between March and June, 2010. Inclusion crite-
ria were 18–75 years of age and a documented increased 
susceptibility to respiratory tract infections, defined as 
>42  days with patient-reported symptoms of respira-
tory tract infection during a 12  months period prior to 
study inclusion. The patients’ diagnosis included selective 
IgA-deficiency (D80.2), IgG-subclass deficiency (D80.3) 
and common variable immune disorder (CVID, D83.0) 
as well as patients without a defined immunological 
diagnosis (D89.9). Exclusion criteria were prophylactic 
treatment with antibiotics, history of hypercalcaemia or 
stones in the urinary tract, sarcoidosis, ongoing supple-
mentation with vitamin D3 exceeding 400  IU/day, HIV-
infection and pregnancy. The raw data is accessed from 
the corresponding author upon request.
The intention to treat (ITT) population included 
n =  140 patients, who were randomized to 12  months’ 
treatment with oral vitamin D3 (Vigantol®, 4000 IU/day) 
or placebo oil (Miglyol). The per protocol population 
(n = 124), who completed the study, consisted of n = 62 
vitamin D treated and n = 62 placebo treated patients.
The primary endpoint was pre-defined as “infectious 
score”, a composite score based on symptoms from 
the respiratory tract, ear, and nose as well as infectious 
malaise and antibiotic consumption. The patients filled 
out a questionnaire every day of the study period. Every 
symptom resulted in one point and the maximum score 
per day was 5 points. A day free of symptoms resulted 
in zero points. The questionnaire and full details of the 
results have been reported in the original publication [8].
To determine the number of RTI a thorough re-analysis 
of the original data-set was performed. One episode of 
RTI was defined as having “at least 2 points per day for 
at least 5 consecutive days”. If symptoms were zero or 1 
point per day or did not last for 5 days or more, no RTI 
episode was recorded. The total number of RTIs was 
recorded for each patient and this information formed 
the basis for this post hoc analysis. In addition, the “time 
to first RTI” in days was also recorded and used for the 
Kaplan–Meier plot described in detail below. The time 
was defined as the number of days from study inclusion 
until the first episode with “at least 2 points per day for at 
least 5 consecutive days”.
Ethical statement
The study was approved by the regional Ethical Review 
Board at Karolinska Institutet, Stockholm, Sweden 
and by the Swedish Medical Products Agency. The 
study was registered at http://www.clinicaltrials.gov 
(NCT01131858) prior to inclusion of the first patient 
(registered March 22, 2010 and approved May 26, 2010) 
and was conducted in accordance with the declaration of 
Helsinki. Written informed consent was obtained from 
all participants prior to inclusion.
Statistical analysis
All statistical tests were performed using GraphPad 
Prism v. 6.00 and p  <  0.05 were considered statistically 
significant.
Number of RTIs during the study
RTI was analysed in two different ways: first, this out-
come was dichotomized (‘any RTI’ = 1 or more; and ‘zero 
RTI’) and analysed with Fishers exact test. Second, the 
total number of RTIs was analysed and due to a skewed 
distribution (many with zero RTIs), the non-parametric 
Mann–Whitney U test was applied.
Kaplan–Meier plot of time to first RTI
A survival analysis was performed to assess the time to 
first RTI in the two groups. The first RTI for all patients 
was connected to a certain day after inclusion. This infor-
mation was plotted in a survival graph (Kaplan–Meier 
plot). Data was analyzed with the log rank Mantel Cox 
test and hazard ratio and the p value were calculated.
Results
Numbers of respiratory tract infections during the study
First, the total number of RTIs was analyzed in a 
dichotomized way (binary), i.e. patients were defined 
in two groups: having “no RTI” or “one or more RTI” 
(range 1–13 RTIs). Notably, a significantly lower frac-
tion of patients in the vitamin D group had one or more 
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RTI during the study (n  =  26/62, 42  %), compared to 
n = 39/62 patients (63 %) in the placebo group (RR 0.64, 
95 % CI 0.43–0.94, Fisher exact test).
Next, the total number of RTIs was studied on the 
group level (vitamin D/placebo). The 62 vitamin D 
patients documented 86 RTIs (median 0 RTI/patient, 
range 0–11), whereas the 62 placebo-patients reported 
120 RTIs in total (median 1 RTI/patient, range 0–13) 
(p = 0.05, Mann–Whitney U test).
Time to first acute respiratory tract infections
The time to first RTI was also identified based on analy-
ses of the original dataset. This information was used to 
perform Cox-analysis between the two groups. Interest-
ingly, the first 120 days, there was no difference between 
the two groups, but after this time the vitamin D group 
clearly had a better outcome with regard to RTI than the 
placebo group (HR 1.68, 95  % CI 1.03–2.68, p =  0.038, 
Log rank Mantel Cox test, Fig. 1).
Discussion
Here we tested the hypothesis that vitamin D supplemen-
tation could reduce the number of—and extend the time 
to—the first RTI, in a group of patients with increased 
susceptibility to RTIs (with and without antibody defi-
ciency). To test this hypothesis we re-analyzed the full 
dataset from the original study and defined the crite-
ria for an ‘RTI-event’ to be “at least 2 points per day for 
at least 5 consecutive days”. By applying this model, we 
could obtain information on the number of RTIs and the 
time to first RTI. This information formed the basis for 
the current report. Notably, vitamin D supplementation 
appeared to decrease the number of RTIs and also pro-
longed the time to first RTI.
One interesting finding was that the beneficial effect 
of vitamin D supplementation appeared after approxi-
mately 3 months (120 days). Notably, this coincided with 
significantly increased serum-levels of 25-OH vitamin 
D in the supplemented individuals, as described in the 
original publication [8], thus strengthening a relationship 
between 25-OH vitamin D levels and RTIs.
The main advantage of redefining the infectious score 
to RTI, is the generalizability of the results, i.e. that the 
results can be compared with other studies. In addition, 
the results are easier to communicate to physicians and 
patients. Although the “infectious score” represents most 
main aspects of having an RTI (symptoms from the res-
piratory tract, ears or sinuses as well as infectious malaise 
and antibiotic consumption), it is a composite score, 
which may be difficult to translate into a clinically mean-
ingful result. In contrast, “the numbers of RTI” and “time 
to first RTI”, are two outcome parameters, which clearly 
have meaning for doctors and health care policy-makers.
Importantly, these results stem from a randomized 
controlled trial (RCT), and carry all the strengths inher-
ent to such a design, including randomization, blinding 
and lack of residual bias.
However, it is important to state that the current study 
is a post hoc analysis of an already published trial [8]. As 
such, the definition of an RTI-event was not predefined 
in the original protocol. Nevertheless, all information to 
calculate the number of RTI and time to RTI was col-
lected during the primary trial. Thus, no additional data 
collection has occurred. It should also be noted that the 
current analysis is performed per protocol and not as 
intention to treat. However, we believe that the per pro-
tocol analysis represent the data in a valid manner, since 
there was an equal amount of patients excluded from 
each arm. The reasons for exclusion were mainly due 
to lack of compliance to the protocol, i.e. not taking the 
drug or not filling out the diary. Importantly, there was 
no tendency that any reason for exclusion was associated 
with a specific allocation (vitamin D/placebo), thus mini-
mizing the risk of bias in a per protocol analysis.
The role of vitamin D in respiratory tract infections 
is still not clear, despite several large RCTs in the area 
(reviewed in [9]). This can probably be explained by the 
large heterogeneity in these RCTs. For example, they 
differ with regard to study population (healthy/disease), 
geographical location (north/south), baseline vitamin D 
levels (deficient or not), dose of vitamin D (high/low), 
dosage regimen (daily/bolus) or study length (months/
years). All these aspects most likely have an impact 
on the outcome of the respective study. Interestingly, 
our study did find a beneficial effect of vitamin D on 
Fig. 1 Time to first acute respiratory tract infection (RTI) in immuno‑
deficient patients treated with vitamin D (4000 IE/day for 1 year) or 
placebo. There was a significantly higher probability to stay infection 
free in the vitamin D‑group (HR 1.68, 95 % CI 1.03–2.68, p = 0.038, 
Log rank Mantel Cox test)
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respiratory tract infection, both in the previous trial 
(endpoint infectious score) [8] but also here (number 
of RTI, time to first RTI). There are several reasons for 
why our study had a positive outcome. For example, we 
studied patients with frequent RTIs (at least 42  days 
with infectious symptoms the year prior to inclusion). 
Further, the baseline vitamin D levels were quite low 
(median 50 nmol/L) and few had levels above 75 nmol/L 
(11  %) or 100  nmol/L (4  %). This is in contrast to the 
VIDAS-trial from New Zealand, with a null result, 
where median levels at inclusion were 75  nmol/L. In 
addition, we used a daily dosing schedule, which have 
been proposed to be superior to a bolus schedule 
(monthly dosing), although this remains to be unequiv-
ocally proven [9].
Our study also had several important limitations. First, 
the definition of a RTI-episode that we chose did not 
take the severity into account. We used “at least 2 points 
for at least 5 consecutive days” as a definition, where 1 
point could involve symptoms from the respiratory tract, 
sinuses or ears or malaise or antibiotics. With this defi-
nition one severe RTI with all symptoms  +  antibiotics 
for a prolonged period would still only count as one RTI. 
This is of course a limitation, but we think that the sever-
ity of RTIs was well covered in the original article where 
the “infectious score” was used as the primary endpoint. 
Here, the aim was to obtain a clinically useful outcome 
and thus we chose “number of RTI” and “time to first 
RTI” as endpoints. Another limitation is that the study 
population was a selected group of patients who are reg-
istered at our tertiary university hospital clinic, with vari-
ous immunological disorders. Thus, the results described 
here cannot be extrapolated to other patient groups or to 
the general public.
The data presented here provide additional evidence 
for a beneficial role of vitamin D in preventing RTIs. 
Although many pieces of key information are still lack-
ing, including the dose, target vitamin D serum lev-
els and populations in need of supplementation, we 
believe that vitamin D should be a parameter to be 
taken into account when meeting patients with fre-
quent respiratory tract infections. It is also important 
to say that we did not record any related adverse events 
(AE); in fact for several types of AEs, there were fewer 
events recorded for the vitamin D group, compared to 
the placebo treated patients [8]. Thus, vitamin D rep-
resents a safe, cheap and potentially important factor 
to correct among vitamin D deficient patients with fre-
quent RTIs.
Given the fact that published RCTs in the area are 
heterogeneous and not conclusive, additional RCTs are 
warranted. These new RCTs should aim to define the 
correct dose, the adequate target vitamin D serum level 
to prevent RTIs and be performed in different disease 
groups, including chronic obstructive pulmonary disease 
(COPD), chronic sinusitis and chronic lung-disease.
Conclusion
In this post hoc analysis of a randomized clinical trial 
vitamin D supplementation was found to significantly 
increase the probability of staying infection free during 
the study period. This finding further support the notion 
that vitamin D-status should be monitored in patients 
with frequent RTIs and that selected patients with vita-
min D-deficiency are supplemented. This could be a safe 
and cheap way to reduce RTIs and improve health in this 
vulnerable patient population.
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